Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of human monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a human monoclonal Antibody (Mab) that is progressing to Phase 2 clinical trials for the treatment of Brain Cancer.
Company profile
Ticker
NBIO
Exchange
Website
CEO
Sean Carrick
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NBIO stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
9 Apr 24
S-1/A
IPO registration (amended)
3 Apr 24
S-1/A
IPO registration (amended)
29 Mar 24
S-1
IPO registration
14 Mar 24
10-Q
2024 Q3
Quarterly report
14 Feb 24
8-K
Other Events
19 Dec 23
10-Q
2024 Q2
Quarterly report
9 Nov 23
8-K
Other Events
6 Sep 23
10-Q
2024 Q1
Quarterly report
18 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.00 mm | 1.00 mm | 1.00 mm | 1.00 mm | 1.00 mm | 1.00 mm |
Cash burn (monthly) | (no burn) | 14.83 k | 279.15 k | 227.21 k | 113.84 k | 126.16 k |
Cash used (since last report) | n/a | 100.62 k | 1.89 mm | 1.54 mm | 772.42 k | 856.04 k |
Cash remaining | n/a | 903.35 k | -890.15 k | -537.74 k | 231.55 k | 147.92 k |
Runway (months of cash) | n/a | 60.9 | -3.2 | -2.4 | 2.0 | 1.2 |
Institutional ownership, Q1 2023
12.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 6.34 mm |
Total shares | 20.74 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
YA II PN | 13.36 mm | $0.00 |
Lorio Sidney J Jr | 7.28 mm | $430.00 k |
Cubic Asset Management | 105.00 k | $5.91 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Douglas John Karas | Common Stock | Other | Acquire J | No | No | 0.1845 | 27,100 | 5.00 k | 1,771,552 |
31 Mar 24 | Holden Lowell Thomas | Common Stock | Other | Acquire J | No | No | 0.1845 | 112,500 | 20.76 k | 9,909,477 |
31 Mar 24 | Carrick Sean | Common Stock | Other | Acquire J | No | No | 0.1845 | 225,000 | 41.51 k | 22,934,007 |
29 Dec 23 | Carrick Sean | Common Stock | Other | Acquire J | No | No | 0.17 | 239,300 | 40.68 k | 22,709,007 |
29 Dec 23 | Holden Lowell Thomas | Common Stock | Other | Acquire J | No | No | 0.17 | 119,650 | 20.34 k | 9,796,977 |